口服抗凝药对髋部骨折患者止血与血栓栓塞并发症影响的系统评价与荟萃分析
该系统评价与荟萃分析纳入21项研究共21417例髋部骨折患者,比较入院前口服抗凝药者与未抗凝者的止血和血栓栓塞结局。口服抗凝药组估计失血量更高(均差31.0 mL,95%CI 6.2-55.7),接受红细胞输注风险为1.34倍(OR 1.34,95%CI 1.20-1.51);术后静脉血栓栓塞(OR 0.96,95%CI 0.40-2.79)和动脉血栓栓塞(OR 0.58,95%CI 0.25-1.36)两组相似。手术延迟程度未减轻该风险,作者认为需紧急评估适时口服抗凝药逆转对血液保护和加速手术的影响。
要点
- 口服抗凝药组估计失血量较未抗凝组高31.0 mL(95%CI 6.2-55.7)。
- 口服抗凝药组接受红细胞输注风险为未抗凝组的1.34倍(OR 1.34,95%CI 1.20-1.51)。
- 术后静脉血栓栓塞(OR 0.96,95%CI 0.40-2.79)与动脉血栓栓塞(OR 0.58,95%CI 0.25-1.36)两组相似。
核心结论
- 髋部骨折口服抗凝药患者手术失血量增加、红细胞输注风险更高,但手术延迟程度未减轻该风险,术后血栓栓塞无差异。
- 作者认为适时口服抗凝药逆转对血液保护和加速手术的影响需紧急评估。
研究设计与样本
- 系统评价与荟萃分析,纳入直接比较入院前口服抗凝药与未抗凝的髋部骨折患者止血和血栓栓塞结局的研究。
- 共纳入21项研究、21417例患者,采用随机效应模型合并估计失血量、输血需求和术后血栓栓塞结局。
主要发现
- 口服抗凝药组估计失血量较未抗凝组高(均差31.0 mL,95%CI 6.2-55.7)。
- 口服抗凝药组接受红细胞输注风险为未抗凝组的1.34倍(OR 1.34,95%CI 1.20-1.51)。
- 术后静脉血栓栓塞两组相似(OR 0.96,95%CI 0.40-2.79)。
- 术后动脉血栓栓塞两组相似(OR 0.58,95%CI 0.25-1.36)。
- 未发现基于抗凝药类型或手术延迟程度的亚组效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为适时口服抗凝药逆转对血液保护和加速手术的影响需紧急评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hip fracture patients on oral anticoagulants (OACs) experience increased time-to-surgery and higher mortality compared to non-anticoagulated patients. However, it is unclear whether pre-injury OAC status and its associated operative delay are associated with worsening of peri-operative hemostasis or an increased risk of postoperative thromboembolism. METHODS: We performed a systematic review to identify studies that directly compared hemostatic and thromboembolic outcomes among hip fracture patients on an OAC prior to admission with those not on anticoagulants. Random effects meta-analyses were used to pool all outcomes of interest (estimated blood loss, transfusion requirements, and postoperative thromboembolism). RESULTS: Twenty-one studies involving 21 417 patients were included. Estimated blood loss was higher among patients presenting with OACs compared to those not anticoagulated (mean difference 31.0 mL, 95% confidence interval [CI] 6.2-55.7). Anticoagulated patients also had a 1.3-fold higher risk of receiving red blood cell transfusions (odds ratio [OR] 1.34, 95% CI 1.20-1.51); however, rates of postoperative thromboembolism were similar regardless of anticoagulation status (OR 0.96, 95% CI 0.40-2.79 for venous thromboembolism; OR 0.58, 95% CI 0.25-1.36 for arterial thromboembolism). No subgroup effect was found based on anticoagulant type or degree of surgical delay. CONCLUSION: Hip fracture patients on OACs experience increased surgical blood loss and higher risk of red blood cell transfusions. However, the degree of surgical delay did not mitigate this risk, and there was no difference in postoperative thromboembolism. The impact of appropriate, timely OAC reversal on blood conservation and expedited surgery in anticoagulated hip fracture patients warrants urgent evaluation.
引用
- Xu Y, You D, Krzyzaniak H, et al. Effect of oral anticoagulants on hemostatic and thromboembolic complications in hip fracture: A systematic review and meta-analysis. J Thromb Haemost. 2020. PMID: 32574420. doi:10.1111/jth.14977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。